Home › Compound Library › Rasagiline (Azilect)

Rasagiline (Azilect)

Nootropicprescriptionoral · inferred

Selective irreversible MAO-B inhibitor for Parkinson's disease (monotherapy in early PD or adjunct with levodopa in advanced). Propargylamine structure (like selegiline) but no amphetamine metabolites. Short plasma half-life ~3h but irreversible binding gives prolonged pharmacodynamic effect. Oral bioavailability ~36%. CYP1A2 metabolized; interactions with ciprofloxacin.

Projected serum levels — 1 mg, once daily

Rasagiline (Azilect)
Rasagiline (Azilect) modeled serum levels, 1 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 1 mg once daily (oral).

Modeled steady state after ~1 days: peak ≈ 0.78 mg, trough ≈ 0.004 mg body load. Population-based estimate over 15 days for a 1 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Nootropic
Route modeled
Oral
Model confidence
inferred
Half-life
3 h
Common dose
1 mg
Suggested maximum
1 mg/day
Reference dose range
0.50–1 mg (single dose)
Suggested cadence
once daily
Validated against
1 mg oral — Cmax 0.008 mg/L at 0.50 h

Documented interactions

  • danger
    1P-LSD (1-Propionyl-LSD) + Rasagiline (Azilect) Serotonin risk

    1P-LSD (1-Propionyl-LSD) and Rasagiline (Azilect) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    25I-NBOMe + Rasagiline (Azilect) Serotonin risk

    25I-NBOMe and Rasagiline (Azilect) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-I (2,5-Dimethoxy-4-iodophenethylamine) + Rasagiline (Azilect) Serotonin risk

    2C-I (2,5-Dimethoxy-4-iodophenethylamine) and Rasagiline (Azilect) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + Rasagiline (Azilect) Serotonin risk

    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and Rasagiline (Azilect) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    3-MeO-PCP (3-Methoxyphencyclidine) + Rasagiline (Azilect) Serotonin risk

    3-MeO-PCP (3-Methoxyphencyclidine) and Rasagiline (Azilect) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    4-AcO-DMT (Psilacetin) + Rasagiline (Azilect) Serotonin risk

    4-AcO-DMT (Psilacetin) and Rasagiline (Azilect) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

Serum checks 98 modeled interaction pairings for rasagiline (azilect) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Clinical pharmacokinetics of rasagiline Chen JJ et al. · Clinical Pharmacokinetics, 2007 DOI

    PK review establishing rasagiline's rapid absorption, ~36% bioavailability, 3h plasma half-life, and CYP1A2-mediated metabolism.

  2. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study Parkinson Study Group · Archives of Neurology, 2002 DOI

    TEMPO trial demonstrating rasagiline monotherapy efficacy in early Parkinson's disease vs placebo, supporting FDA approval.

2 published studies referenced in the app, each with a plain-language summary.